Repurposed Therapeutics, Inc.

ACTIVE

12935 N 40 Dr Ste 212, Saint Louis, 佛罗里达州, United StatesPrivate

Also known as:

defender pharmaceuticals

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

54.5%

Phase 2

36.4%

Phase 1

9.1%

Trial Status Distribution

Completed

45.5%

Recruiting

18.2%

Terminated

18.2%

Unknown

18.2%

Clinical Trials

Trials sponsored by this organization (11)

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Phase 3

Completed

interventional

Aug 2022503 participants

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Phase 2

Recruiting

interventional

Jan 202230 participants

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Phase 2

Recruiting

interventional

Aug 202180 participants

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Phase 3

Completed

interventional

Jun 2021140 participants

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

Phase 3

Completed

interventional

Jun 2019102 participants

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Phase 3

Completed

interventional

Jun 201998 participants

The Prevention and Treatment of Nausea Associated With Motion Sickness

Phase 3

Completed

interventional

Apr 2019300 participants

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

Phase 3

Unknown

interventional

Apr 2019300 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations